Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound

This article was originally published in PharmAsia News

Executive Summary

Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan

You may also be interested in...



Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia

Deal to build integrated Bangalore facility cements ten-year partnership between the U.S. pharma and the Indian contract research organization.

Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia

Deal to build integrated Bangalore facility cements ten-year partnership between the U.S. pharma and the Indian contract research organization.

After 10-year Partnership, Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center In Asia

MUMBAI - Bristol-Myers Squibb and Syngene - Biocon's contract research services arm - cemented a 10-year long association with the opening of what is called Asia's largest research facility near Bangalore. Syngene was established in 1994 and was the first to offer contract research services out of India. Syngene has now grown to become Biocon's fastest growing arm and has research alliances with Novartis and Merck

Related Content

UsernamePublicRestriction

Register

SC071255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel